Lead Product(s) : Tafamidis
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NICE Says ‘No’ to Pfizer’s Vyndaqel for Rare Heart Condition
Details : NICE is willing to conduct a rapid review of Vyndaqel (tafamidis) used for treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Product Name : Vyndaqel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2021
Lead Product(s) : Tafamidis
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
